University of Missouri - Columbia
Columbia, Missouri, 65212, United States
Location status: Recruiting
Location contact
Jennifer Randolph, RN, BSN
CONTACT
Jonathan Bath, MD
CONTACT
NCT Number: NCT06411990
The goal of this clinical trial is to learn about a new device, named the LIFE device, to treat people with aneurysms (swellings) in the aorta (large, main blood vessel that delivers blood from the heart to the body). The main questions this trial aims to answer are:
* If the LIFE device works to treat aortic aneurysms * What medical problems participants have when the LIFE device is used Participants will undergo treatment with the LIFE device and thereafter at 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years have their pulses checked, bloodwork to check kidney function (BUN and serum creatinine), and a CT scan of the aneurysm area.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Columbia, Missouri, 65212, United States
Location status: Recruiting
Jennifer Randolph, RN, BSN
CONTACT
Jonathan Bath, MD
CONTACT
In this clinical trial the LIFE device is used to treat people with aneurysms in the aorta near the kidney arteries (called juxtarenal or pararenal aortic aneurysms). Tubes, called stent grafts, are typically inserted through blood vessels in the groin and placed inside the aorta in the abdomen and chest area (endovascularly placed) to cover the tear or leak in the aorta. The LIFE device covers the tear or leak and has side branches to let blood flow into the kidney, spleen, intestine, or liver arteries. Participants in this study are not candidates for endovascular devices approved for endovascular aorta repair to the juxtarenal or pararenal aorta, not candidates for open repair, not willing to travel to sites that have access to manufacturer-made endovascular devices, and patients for whom there are no favorable alternatives, for example, urgent, symptomatic, and emergency cases.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fenestrated Endovascular Aneurysm Repair
Other names: Medtronic Valiant Thoracic Stent Graft with the Captive Delivery System, Medtronic Endurant II Stent Graft System, Medtronic Endurant IIs Stent Graft System and/or, Medtronic Endurant Aorto-uni-iliac (AUI) Stent Graft System, GORE VIABAHN VBX Balloon Expandable Endoprostheses, Spectranetics CVX-300 Excimer Laser System with the Spectranetics Turbo-Elite Laser Atherectomy Catheter
Time frame: 30 days
Number of subjects with freedom from all cause mortality and freedom from major adverse events. Major adverse events include myocardial infarction, chronic renal insufficiency / chronic renal failure requiring, dialysis, bowel ischemia, stroke, paraplegia or paraparesis, and prolonged ventilatory support.
Time frame: 12 months
Device technical success (at the end of index procedure) and freedom from Type I and III endoleak, device migration ≥ 10 mm, aortic enlargement ≥ 5 mm, aortic rupture, and aortic or branch-related reinterventions, including conversion to open repair (within 12 months of the index procedure)
Time frame: Procedure
Ability to deliver and deploy the LIFE Device System
Time frame: Procedure
Ability to deliver and deploy the thoracic/abdominal stent graft
Time frame: Procedure
Ability to cover the intended aneurysm
Time frame: Procedure
Contrast flow into the target renovisceral vessels
Time frame: Procedure
Estimated blood loss
Time frame: From Procedure until the date of Hospital Discharge, typically 1-2 days
Ventilator days
Time frame: From Procedure until the date of Hospital Discharge, typically 1-2 days
Days to oral intake
Time frame: From Procedure until the date of Hospital Discharge, typically 1-2 days
ICU days recorded
Time frame: From Procedure until the date of Hospital Discharge, typically 1-2 days
Days to hospital discharge
Time frame: Procedure
Procedure time (minutes)
Time frame: Procedure
Fluoroscopy time (minutes)
Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Endoleak rate at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Device integrity failure (e.g., fracture) at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Branch vessel device events (i.e., kink, stenosis, or occlusion at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Aortic growth - defined as an increase ≥ 5 mm in maximal aortic diameter in any segment at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Time frame: 5 Years
Unplanned secondary procedures throughout follow-up (e.g., unanticipated aortic or branch-related reoperation)
Time frame: 6 Months, and 1, 2, 3, 4, and 5 Years
Device migration (radiographic), antegrade or retrograde movement of more than 10 mm relative to anatomic landmarks identified on the first (30 Day) post-operative CT scan, at 6 Months, and 1, 2, 3, 4, and 5 Years
Time frame: 5 Years
All adverse events throughout 5 year follow-up, including if MAE, serious adverse event (SAE) or unanticipated adverse device effect (UADE), and the relationship of the AE to the LIFE Procedure and LIFE Device System
Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Freedom from aneurysm-related mortality at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years
Time frame: 6 Months and 1, 2, 3, 4, and 5 Years
Freedom from all-cause mortality at 6 Months and 1, 2, 3, 4, and 5 Years
Contact information is provided by the study sponsor or research team.
Jonathan Bath
Other
Laser In Situ Fenestration for Endovascular Aortic Repair (LIFE) Study
Acronym: LIFE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07078383
Acute Aortic Syndrome, Aneurysm
Los Angeles, California, United States
View Trial DetailsNCT07611968
Aneurysm, Aortic Aneurysm
Jacksonville, Florida, United States
View Trial DetailsNCT06549348
Aneurysm, Aortic Aneurysm
Birmingham, Alabama, United States
View Trial DetailsNCT06286358
Aneurysm, Aortic Aneurysm
Brussels, Belgium
View Trial Details